Protego Biopharma Raises $130 Million Oversubscribed Series B Financing to Advance First-in-Class AL Amyloidosis Program into Pivotal Study

Protego Biopharma Raises $51 Million Series A Financing to Advance the Treatment of Protein Misfolding Diseases